Short answer
ABEONA THERAPEUTICS INC. (ABEO) filed an 8-K current report with the SEC on April 7, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expanded from 9 to 10 directors, adding Keith A. Goldan as a Class 1 director through the 2026 annual meeting.
ABEONA THERAPEUTICS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from 9 to 10 directors, adding Keith A. Goldan as a Class 1 director through the 2026 annual meeting
- Goldan appointed Audit Committee Chair, strengthening independent financial oversight
- Nasdaq-qualified independent director with no disclosed related-party transactions or appointment arrangements
- Compensation includes $50,000 annual cash fee and $150,000 restricted-stock sign-on grant vesting over one year
Item 7.01 · Regulation FD Disclosure
- Press release announces Mr. Goldan’s appointment to Abeona’s Board on April 7, 2026
- Board appointment may influence governance and strategic oversight
- Exhibit 99.1 contains the substantive appointment details
Item EX-99.1 · Exhibit EX-99.1
- Keith A. Goldan appointed independent director effective April 1, 2026
- Goldan becomes Audit Committee Chairman, strengthening financial oversight during commercial launch
- His commercialization, capital-markets, and M&A experience aligns with ZEVASKYN’s first U.S. launch
- Appointment signals board focus on scaling operations and financing Abeona’s commercial-stage growth
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ABEONA THERAPEUTICS INC. 8-K filings
Get the next ABEO 8-K as it lands
Follow ABEO for push alerts, or ask the research agent what this filing means.